Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate
June 17, 2022 01:00 ET
|
Addex Therapeutics
COVID-19 related challenges negatively impacted patient recruitment Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 17, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN),...
Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study
May 27, 2022 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 27, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Announces Participation in the H.C. Wainwright Global Investment Conference
May 19, 2022 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Announces Participation in the 22nd Bio€quity Europe Conference
May 13, 2022 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Shareholders Approve All Resolutions at Annual General Meeting
May 10, 2022 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug...
Addex Reports Q1 2022 Financial Results
May 05, 2022 01:00 ET
|
Addex Therapeutics
CHF14.9M ($16.1M) of cash and cash equivalents at March 31, 2022Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022Phase 2b/3 dipraglurant study in dyskinesia...
Addex to Present at the Swiss Biotech Day 2022
April 28, 2022 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, April 28, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex to Present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference
April 25, 2022 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, April 25, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study
April 13, 2022 01:00 ET
|
Addex Therapeutics
Top-line Data Scheduled to Report in Q2 2022 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a...
Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders
April 06, 2022 01:00 ET
|
Addex Therapeutics
New Series of Potent and Selective Compounds Identified Using Proprietary Allosteric Modulator Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 6, 2022 -...